Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6

Leukemia Research

Volumn 33, Issue 1, 2009, Pages 115-122

  Hongming, Huang ^a   Jian, Hou ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; Multiple myeloma; Osteoclast; TRAF6 (tumor necrosis factor receptor associated factor 6)

Indexed keywords

BORTEZOMIB; COLONY STIMULATING FACTOR 1; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ARTICLE; BONE ATROPHY; CANCER PATIENT; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CELL SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; OSTEOCLAST; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STEM CELL;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BORONIC ACIDS; CELL DIFFERENTIATION; DOWN-REGULATION; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MONOCYTES; MULTIPLE MYELOMA; OSTEOCLASTS; PYRAZINES; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 55049087150     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.07.028     Document Type: Article

References (29)

1. Roodman G.D. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32 (2004) 290-292
2. Berenson J.R. Myeloma bone disease. Best Pract Res Clin Haematol 18 (2005) 653-672
3. Silvestris F., Lombardi L., De Matteo M., Bruno A., and Dammacco F. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Leuk Res 31 (2007) 129-138
4. Yaccoby S., Wezeman M.J., Zangari M., et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 91 (2006) 192-199
5. Abe M., Hiura K., Wilde J., et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104 (2004) 2484-2491
6. Giuliani N., Colla S., and Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 32 (2004) 685-691
7. Sezer O., Heider U., Jakob C., et al. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 99 (2002) 4646-4647 [author reply 4647]
8. Terpos E., Szydlo R., Apperley J.F., et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102 (2003) 1064-1069
9. Buckley K.A., Chan B.Y., Fraser W.D., and Gallagher J.A. Human osteoclast culture from peripheral blood monocytes: phenotypic characterization and quantitation of resorption. Methods Mol Med 107 (2005) 55-68
10. Lomaga M.A., Yeh W.C., Sarosi I., et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13 (1999) 1015-1024
11. Naito A., Azuma S., Tanaka S., et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4 (1999) 353-362
12. Mizukami J., Takaesu G., Akatsuka H., et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol 22 (2002) 992-1000
13. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96 (1999) 3540-3545
14. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
15. Deng L., Wang C., Spencer E., et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103 (2000) 351-361
16. Lamothe B., Besse A., Campos A.D., Webster W.K., Wu H., and Darnay B.G. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem 282 (2007) 4102-4112
17. Hideshima T., Mitsiades C., Akiyama M., et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101 (2003) 1530-1534
18. Hideshima T., Chauhan D., Richardson P., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277 (2002) 16639-16647
19. Nencioni A., Grunebach F., Patrone F., Ballestrero A., and Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 21 (2007) 30-36
20. Terpos E., Dimopoulos M.A., and Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 21 (2007) 1875-1884
21. Terpos E., Sezer O., Croucher P., and Dimopoulos M.A. Myeloma bone disease and proteasome inhibition therapies. Blood 110 (2007) 1098-1104
22. Terpos E., Heath D.J., Rahemtulla A., et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 135 (2006) 688-692
23. Roodman G.D. Bone building with bortezomib. J Clin Invest 118 (2008) 462-464
24. von Metzler I., Krebbel H., Hecht M., et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 21 (2007) 2025-2034
25. Zavrski I., Krebbel H., Wildemann B., et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 333 (2005) 200-205
26. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., and Baldwin Jr. A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281 (1998) 1680-1683
27. Mani A., and Gelmann E.P. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23 (2005) 4776-4789
28. Tenno T., Fujiwara K., Tochio H., et al. Structural basis for distinct roles of Lys63- and Lys48-linked polyubiquitin chains. Genes Cells 9 (2004) 865-875
29. Asagiri M., and Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 40 (2007) 251-264